CBDepot and CB21 Pharma exhibit Czech-made EU GMP cannabis-derived APIs at CPHI Barcelona

news-releasesCBDepot s.r.o.
October 5th 2023

Prague, Czechia: – Pioneering ethical cannabinoid sister companies CBDepot and CB21 Pharma will jointly exhibit at Europe’s leading pharma industry event, the CPHI 2023 trade expo, this October in Barcelona.

CBDepot has a close relationship with CPHI, choosing the Worldwide show in Frankfurt in 2017 to introduce the world’s first pharma grade EU GMP cannabidiol (CBD) isolate.

Pharma- and food-grade cannabinoids

From their stand at Booth 80C32 in the Fira Barcelona Gran Via, CB21 Pharma and CBDepot will showcase their impressive portfolio of cannabis-derived APIs manufactured in compliance with EU GMP regulations, including pharma-grade, Cannabis Extractum Raffinatum and Extractum Normatum, along with Dronabinol (delta-9-tetrahydrocannabinol, THC).

They will also be showing CBDepot’s broad range of food-grade isolated and synthesized cannabinoids and extracts, many of which are now validated as novel food ingredients in the UK and EU.

Manufactured in Czechia

All CBDepot and CB21 products are manufactured in the Czech Republic, which is becoming a leading source for ethical cannabis-derived products. CBDepot CEO Jan Storch and Global Substance Sales Director Boris Baňas will jointly host a webinar on October 17, a week before CPHI 2023 opens, on ‘Czech-Made EU GMP Cannabis-Derived APIs’.

The session will discuss the expanded portfolio of EUDRA-listed EU GMP CBD and EU GMP cannabis extracts fit for clinical trials and medicine development that can now be sourced from Czechia. Registration for the webinar is free of charge and can be completed online (See Resources).

A maturing industry

Boris Baňas commented: “Once again we are looking forward to attending CPHI as a brilliant venue to meet partners and stakeholders and to explore exciting opportunities for the fast-growing cannabinoid ingredient sector., which is now being taken seriously as a mature industry sector” said Mr. Baňas.

About CBDepot and CB21 Pharma

Founded in 2015, CBDepot has established itself as a pioneering producer and B2B supplier of upmarket cannabinoid solutions, playing a leading role in creating legal and quality standards for cannabinoid ingredients and the formulation of cannabidiol derivatives.

With its sister company, CB21 Pharma, this Czech group of innovative companies serves fast-growing markets in the food, cosmetics, pharmaceuticals, and health products sectors with high-quality natural and synthesized cannabinoids and cannabis-derived ingredients.

CBDepot’s current strapline “Upmarket Cannabinoid Solutions “reflects its new ability to offer cannabinoid ingredients and substances to various markets such as: cosmetic, food, and food supplements, with Europe-wide recognition as a strong, ethical and transparent supplier of cannabinoids. Meanwhile, CB21 Pharma has become a fully certified pharmaceutical company that manufactures cannabis-derived isolates and extracts to EU GMP standards.

CB21 Pharma is a pharmaceutical company established in autumn 2018. It focuses on developing treatments based on non-psychotropic cannabinoids combined with other active substances and has pioneered innovative medical therapies and functional cosmetics.

The companies share a common heritage and many key personnel, including Chief Sales Officer, Boris Baňas, formerly a board member of the European Industrial Hemp Association (EIHA), where he successfully campaigned for the establishment of new Europe-wide standards. CBDepot’s scientific knowledge is based on close links with the Czech Academy of Sciences.

Learn more at www.cbdepot.eu

About CPHI Barcelona 2023

Now in its 34th year, CPHI continues as the flagship European annual trade show for pharma ingredients and partner sourcing, with a refreshed mission to be the industry’s main enabler for sustainability, whilst also being an environmentally and socially responsible event.

The sustainability agenda is partly reflected in the 2023 CPHI conference agenda, with emphasis on NextGen Biomanufacturing, Formulating the Future, Patient-Centric Development, and Creating a Circular Economy, along with Future Therapies, Manufacturing 4.0, Quality Management Fundamentals and BioProduction.

It is also reflected in the hybrid model that fuses a large physical expo with an online dimension to make networking and browsing easier and to extend the time frame of the event indefinitely.

For 2023, CPHI Barcelona is a three-day physical event opening October 24 at the Fira Barcelona Gran Via expo center, with the online dimension now accessible all year round.

The previous ‘seven shows in one’ format has now been replaced by a more integrated main CPHI event featuring exhibitor zones for Machinery & Equipment, Finished Dosage, Packaging & Drug Delivery, Contract Manufacturing & Services, APIs, Excipients, Integrated Pharma, Natural extracts, and Fine Chemicals

CPHI Barcelona is organised by Informa Markets with further information at: www.cphi.com/europe/en/home.html


Click on Czech-Made EU GMP Cannabis-Derived APIs to register for webinar.
Click on CBDepot at CPHI Barcelona to Book a face to face or online meeting with CBDepot/CB21 Pharma and to see exhibitor profile.
Click on News from CBDepot for further developments at CBDepot.

CBDepot and CB21 Pharma exhibit Czech-made EU GMP cannabis-derived APIs at CPHI Barcelona

CBDepot and CB21 Pharma will exhibit their pharma grade high purity trans-Cannabidiol (CBD) isolates and synthesized powders.

CBDepot and CB21 Pharma exhibit Czech-made EU GMP cannabis-derived APIs at CPHI Barcelona

Boris Baňas, Chief Scientific Officer, CBDepot.

CBDepot and CB21 Pharma exhibit Czech-made EU GMP cannabis-derived APIs at CPHI Barcelona

CBDepot CEO Jan Storch.